Merck Stock Drops 1.86% Despite FDA Approval for Keytruda, Ranks 67th in Trading Volume

On May 8, 2025, Merck & Co., Inc. (MRK) experienced a decline of 1.86% in its stock price, with a trading volume of 11.71 billion, ranking 67th in the day's market activity.

Merck's stock price has been influenced by several key developments. The company recently announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its new drug, Keytruda, which is designed to treat a specific type of cancer. This approval is expected to boost Merck's revenue and market share in the oncology sector.

Additionally, Merck has been actively involved in expanding its research and development efforts. The company has invested heavily in clinical trials for several new drugs, aiming to address unmet medical needs. These investments are part of Merck's long-term strategy to maintain its leadership position in the pharmaceutical industry.

Merck's financial performance has also been a topic of discussion. The company reported strong earnings for the first quarter of 2025, driven by robust sales of its key products. Analysts have praised Merck's ability to navigate the competitive landscape and deliver consistent growth.

Despite these positive developments, Merck faces challenges in the form of regulatory hurdles and competition from other pharmaceutical companies. The company is working to address these challenges by focusing on innovation and strategic partnerships.